The spread of antibiotic resistance and new options for combating it
- Project team:
- Thematic area:
Biotechnology and health, Energy and environment, Agriculture and food
- Topic initiative:
Committee on Research, Technology, Space and Technology Assessment, and the Parliamentary Advisory Council on Sustainable Development and Future-Related Matters
- Analytical approach:
TA project
- Startdate:
September 2026
- Enddate:
2028
sprungmarken_marker_5316
Thematic background
Antimicrobial resistance (AMR), particularly antibiotic resistance in bacterial pathogens, has become one of the most serious threats to global public health. Beyond the challenges posed by treating infectious diseases, antibiotic-resistant bacterial pathogens – including those resistant to various antibiotics or last-resort antibiotics – pose a significant challenge to standard medical procedures. In Germany alone, an estimated 41,000 deaths in 2021 were associated with bacterial antibiotic resistance, including around 8,000 deaths directly attributable to AMR. Furthermore, antibiotic resistance plays a significant role in septic infections, which are often associated with long-term damage and the need for ongoing care among survivors. Some forecast models predict that global deaths linked to antibiotic resistance could rise by around 70 per cent by 2050, reaching roughly 9 million deaths annually, unless effective countermeasures are implemented. In high-income countries, the predicted increase would be driven by a doubling of deaths among people over the age of 70.
The global spread of antibiotic resistance and antibiotic-resistant pathogens is attributed to the excessive and indiscriminate use of antibiotics in human medicine, as well as the poorly controlled use of antibiotics in agriculture, particularly in intensive livestock production. However, the extent to which the use of antibiotics in livestock production contributes to the emergence and spread of antibiotic resistance, particularly in the case of pathogens that are not transmissible from animals to humans, has not yet been conclusively clarified.
Various measures are considered important for combating antibiotic resistance. These typically form part of antibiotic resistance strategies and action plans in many countries, including Germany. These measures include efforts to optimise antibiotic use, such as education and awareness campaigns, infection prevention through improved hygiene and vaccination, and reducing the extensive use of antibiotics in medicine and agriculture, as well as their release into the environment (the One Health approach). On the other hand, new, effective antibiotics or alternative antibacterial medicines must be developed and deployed as selectively as possible. In this context, the promotion of research and development, as well as new approaches to innovation policy and regulation, are considered essential for overcoming the economic challenges and profitability issues that new antibacterial medicines face following market authorisation.
Objectives and approach
As part of a TA project initiated by the Committee on Research, Technology, Space and Technology Assessment and the Parliamentary Advisory Council on Sustainable Development and Future Issues, TAB is examining the spread of antibiotic resistance, emerging strategies for combating it, and potential innovations relevant to German health policy.
To this end, four sets of questions are to be examined:
- The current state of knowledge regarding the routes of introduction and spread of antibiotic resistance and (multi-)resistant bacteria, and their past and expected impacts on human health and potential societal costs, under different future scenarios, at a global level, in different regions (including the EU), and nationally.
- Developments and new opportunities in biotechnological and pharmaceutical research into new antibiotics, alternative antimicrobial agents and therapies (e.g. phages and phage-derived proteins, antibodies, and immunomodulatory approaches), and vaccines.
- The opportunities for using artificial intelligence to fight antibiotic resistance, particularly to enable rapid diagnosis of bacterial infections in human medicine and livestock production, to monitor antibiotic resistance in the environment, and to develop new antibacterial medicines and vaccines.
- Innovation policy and regulatory models under discussion (and, where applicable, results from models currently being piloted or tested), which are designed to promote the development of new pharmaceutical products and therapies, or address challenges to the limited commercial viability of new antibacterial medicines after market authorisation.
Based on these analyses, TAB will produce a report providing a comprehensive and up-to-date assessment of the spread of antibiotic resistance and recent developments in efforts to combat it. The report will identify the associated opportunities and challenges and outline possible policy options for action.